Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics-Reference-Cited by-同舟云学术

Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics

Published:2016-08-31 Issue:8 Volume:11 Page:e0161009
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yoneyama Toshihiro,Ohtsuki Sumio,Honda Kazufumi,Kobayashi Makoto,Iwasaki Motoki,Uchida Yasuo,Okusaka Takuji,Nakamori Shoji,Shimahara Masashi,Ueno Takaaki,Tsuchida Akihiko,Sata Naohiro,Ioka Tatsuya,Yasunami Yohichi,Kosuge Tomoo,Kaneda Takashi,Kato Takao,Yagihara Kazuhiro,Fujita Shigeyuki,Huang Wilber,Yamada Tesshi,Tachikawa Masanori,Terasaki Tetsuya

Funder

Ministry of Education, Culture, Sports, Science, and Technology

Japan Society for the Promotion of Science

Cabinet Office, Government of Japan

Ministry of Health, Labour and Welfare

Japan Agency for Medical Research and Development

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference56 articles.

1. Cancer statistics, 2014;R Siegel;CA Cancer J Clin,2014